IP Library › Granted Patent US 8,653,081
Granted Patent B2
US 8,653,081 · App. 13/853,352 · Granted Feb 18, 2014

Certain chemical entities, compositions, and methods

Inventors: Bradley P. Morgan (Moraga, CA); Erica A. Kraynack (Belmont, CA); Pu-Ping Lu (Foster City, CA); Alex Muci (San Francisco, CA); David J. Morgans (Los Altos, CA)
Assignee: Cytokinetics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,653,081
App. No.
13/853,352
Granted
Feb 18, 2014
Kind
B2
Abstract

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Claims (16)

1. A compound of the formula

or a pharmaceutically acceptable salt thereof,

where one of Z 1 and Z 2 is —NR 15 C(O)NR 16 R 4 and the other of Z 1 and Z 2 is R 3 ;

R 4 is optionally substituted heteroaryl;

R 3 is chosen from hydrogen, halo, cyano, hydroxyl, optionally substituted alkyl, optionally substituted heterocycloalkyl, and optionally substituted heteroaryl;

R 1 and R 2 are independently chosen from hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted heterocycloalkyl, and optionally substituted heteroaryl;

R 15 and R 16 are independently chosen from hydrogen, and optionally substituted alkyl;

R 5 is optionally substituted piperazinyl; and

L is lower alkylene.

2. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is chosen from 4-(dimethylcarbamoyl)piperazine-1-yl, 4-(N,N-dimethylsulfamoyl)piperazine-1-yl, 4-acetyl-piperazin-1-yl, 4-ethoxycarbonyl-piperazin-1-yl, 4-ethylsulfonyl-piperazin-1-yl, 4-methoxycarbonyl-piperazin-1-yl, 4-methylsulfonyl-piperazin-1-yl, 4-t-butoxycarbonyl-piperazin-1-yl, piperazin-1-yl, 4-(4-acetylpiperazine-1-carbonyl)piperazin-1-yl, 4-(4-methylpiperazine-1-carbonyl)piperazin-1-yl, 4-(piperidine-1-carbonyl)piperazin-1-yl, 4-(morpholine-4-carbonyl)piperazin-1-yl, 4-(cyclobutylsulfonyl)-piperazin-1-yl, 4-(ethylsulfonyl)piperazin-1-yl, 4-(isopropylsulfonyl)piperazin-1-yl, 4-(cyclopropylsulfonyl)piperazin-1-yl, and 4-(1,1-dioxide thiomorpholine-4-carbonyl)piperazin-1-yl.

3. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is chosen from optionally substituted pyridinyl.

4. A compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein R 4 is chosen from 6-methoxy-pyridin-3-yl, 6-methyl-pyridin-3-yl and pyridin-3-yl.

5. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is chosen from hydrogen, halo, cyano, lower alkyl, and hydroxyl.

6. A compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 3 is chosen from hydrogen, fluoro, chloro, methyl, ethyl and hydroxyl.

7. A compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are independently chosen from hydrogen, halo, cyano and lower alkyl.

8. A compound of claim 1 , or a pharmaceutically acceptable salt thereof where R 1 , R 2 and R 3 are hydrogen.

Continuity (4)
Division 12772872 · May 3, 2010
Division 11639390 · Dec 13, 2006
Provisional Application 60751118 · Dec 16, 2005
Related Publication 20130296335A1 · Nov 7, 2013